Introduction
Hand eczema or hand dermatitis is defined as an inflammation of the skin of the hands. 1 This itchy skin condition of hands usually presented with erythema, edema and occasionally vesicles in acute stage; whereas chronic hand eczema lichenification, scaling and fissures are prominent. 2 The world-wide prevalence of hand dermatitis among different racial and occupational groups ranges from 4 to 10%. 2 The most common causes are allergic contact dermatitis (19%), irritant contact dermatitis (35%), atopic dermatitis (22%) and others such as nummular hand eczema, hyperkeratotic hand eczema, or pompholyx. 3 Among the different treatment options of hand eczema, topical corticosteroids are mostly used. 4-6 Long-term potent topical steroids are effective but the skin atrophy, infection, hypertrichosis, tachyphylaxis and adrenal suppression are among many cutaneous and systemic adverse effects. 7 Triamcinolone acetonide is a synthetic corticosteroid and effective in the treatment various skin conditions. It is a more potent derivative of triamcinolone and about eight times stronger than prednisolone. 8 Intralesional application of corticosteroid is used to treat a dermal inflammatory process directly deliver and maintain a high concentration of the drug at the pathologic site, with less systemic absorption. 9 It avoids the thickened stratum corneum, minimize epidermal atrophy and deliver higher concentration to the site of pathology. 8-9 Therefore, the purpose of the present study was to assess the efficacy and safety of intralesional triamcinolone acetonide in patients with chronic hand eczema comparing with topical clobetasol propionate.
Materials and Methods
It was a randomized controlled clinical trial, carried out from April to September 2014. It was conducted as a dissertation after approval of the protocol by Bangladesh College of Physicians and Surgeons (No. CPS-7/2014/DSN 2015 -010008). Sixty clinically and histopathologically diagnosed cases of chronic hand dermatitis of the duration of more than three months were selected after taking informed written consent and enrolled randomly into two groups: Group A (case) and B (control). In Group A, patients were given 0.1 mL injection of 40 mg/mL strength triamcinolone acetonide per square cm of involved area intralesionally and were repeated at 28 days interval on 4 th and 8 th week. Patients of control group were given | Clinical | Trial |
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In addition to that, adverse reactions like striae, telangiectasia, thinning of the skin, hypertrichosis were also recorded. There was no case of drop out in any treatment group. 
Results
The mean age of Group A (32.4 ± 10.2 years) was higher than Group B (29.6 ± 10.0 years) but the difference was not statistically significant (p>0.050) ( Table I ). The male female difference between these two groups was not statistically significant (p>0.050). In Group A, 33.3% patients were housewife followed by same were service holder, 20.0% were students and 13.3% were business person. In Group B, 33.3% patients were the business person followed by 26.7% were the student, 20.0% were service holder and same were the housewife. The difference between these two groups was not statistically significant (p>0.050).
The initial HECSI score in Group A was 33 (12-148), at 4 th week 20 (0-105) and at 12 th week 20 (0-80) (Table II) . In Group B, it was 54 (30-152) initially, then 10 (0-34) and 8 (0-49) at 4 th and 12 th week respectively. In both groups, HECSI score was decreased gradually but the rate was higher in Group B than the Group A. In each follow-up, the difference between two groups was statistically significant (p<0.050).
Thinning of skin was seen in 10.0% patients of Group A and 16.7% patients in Group B. Difference between these two groups was not statistically significant (p>0.050).
Discussion
The current study was conducted to compare the efficacy intralesional triamcinolone acetonide with topical clobetasol propionate in the treatment of chronic hand eczema. In both groups, HECSI score decreased gradually but the rate was higher in Table II HECSI score before treatment and after treatment in study patients Mann-Whitney U-test is done to measure the level of significance group B than A. In each follow-up the difference between two groups was statistically significant (p<0.050) (Table III) .
It has been well established that topical steroids are the mainstay of the pharmacological treatment of hand eczema. 5, 11 Long-term potent steroids are very effective; however, the adverse effects like skin atrophy, tachyphylaxis, and adrenal suppression are well-known and after a few weeks of twice daily use it is recommended to use them on every alternate day or twice in a week. 7 Similar to the present study Möller, et al (1983) compared longterm, intermittent maintenance treatment of chronic hand eczema with clobetasol propionate comparing other topical steroid and have found that the dermatitis of 90% of these patients have been cleared. 12 No previous study has been found comparing the efficacy of topical clobetasol with intralesional triamcinolone in the treatment of hand eczema. Here, severity of hand eczema (HECSI score) reduced gradually in both intralesional triamcinolone treated group and topical clobetasol treated group but the rate was significantly higher in clobetasol treated group (p<0.050). Regarding the adverse reaction thinning of skin was seen in 10.0 and 16.7% patients in group A and B respectively (p>0.050). Alcers (1980) has shown that the common risk of long-term use of topical potent steroid is thinning of skin. 7 Here, thinning of the skin with topical clobetasol propionate is comparable with that of intralesional triamcinolone acetonide.
Conclusion
Intralesional triamcinolone acetonide is effective in the treatment of hand eczema but efficacy is significantly less than that of topical clobetasol propionate with comparable safety.
